Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WellPoint Will Put Comparative Effectiveness Guidance In Updated Drug Assessment Criteria

This article was originally published in The Pink Sheet Daily

Executive Summary

The health insurer's next iteration of its technology assessment criteria, used for evaluating drugs for formulary inclusion, will likely be published by the end of the year.

You may also be interested in...



WellPoint's Comparative Effectiveness Research Guidelines Describe How It Will Determine Usefulness Of Studies

The largest provider of health benefits in the U.S. will use the CER guidelines when evaluating drugs for its formulary.

WellPoint's Comparative Effectiveness Research Guidelines Describe How It Will Determine Usefulness Of Studies

The largest provider of health benefits in the U.S. will use the CER guidelines when evaluating drugs for its formulary.

Senate Considers Revised Comparative Effectiveness Plan In Reform Bill

Comparative effectiveness research led by a non-government institute with funding from public and private sources, as envisioned by Sen. Max Baucus, D-Mont., is among the provisions for health care reform that are being debated by the Senate, but some changes to CER provisions were made as the bill moved from the Finance Committee to its current iteration on the Senate floor

Related Content

Topics

UsernamePublicRestriction

Register

PS070489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel